Share
Export Citation
Solid Dispersion Incorporated into Dissolving Microneedles for Improved Antifungal Activity of Amphotericin B: In Vivo Study in a Fungal Keratitis Model
Mahfud M.A.S.
Molecular Pharmaceutics
Q1Abstract
Fungal keratitis (FK) is a fungal infection of the cornea, which is part of the eye and causes corneal ulcers and an increased risk of permanent blindness, which is often found in <i>Candida albicans</i> species. Amphotericin B (AMB), which is a group of polyenes as the first-line treatment of FK, is effective in annihilating <i>C. albicans</i>. However, AMB preparations such as eye drops and ointments have major drawbacks, for instance, requiring more frequent administrations, loss of the drug by the drainage process, and rapid elimination in the precornea, which result in low bioavailability of the drug. An ocular dissolving microneedle containing the solid dispersion amphotericin B (DMN-SD-AMB) had been developed using a mixture of poly(vinyl alcohol) (PVA) and poly(vinylpyrrolidone) (PVP) polymers, while the solid dispersion AMB (SD-AMB) was contained in the needle as a drug. This study aims to determine the most optimal and safest DMN-SD-AMB formula for the treatment of FK in the eye as well as a solution to overcome the low bioavailability of AMB eye drops and ointment preparations. SD-AMB had been successfully developed, which was characterized by increased antifungal activity and drug release <i>in vitro</i> compared to other treatments. Furthermore, DMN-SD-AMB studies had also been successfully performed with the best formulation, which exhibited the best <i>ex vivo</i> corneal permeation profile and antifungal activity as well as being safe from eye irritation. In addition, an <i>in vivo</i> antifungal activity using a rabbit infection model shows that the number of fungal colonies was 0.98 ± 0.11 log<sub>10</sub> CFU/mL (F3), 5.76 ± 0.32 log<sub>10</sub> CFU/mL (AMB eye drops), 4.01 ± 0.28 log<sub>10</sub> CFU/mL (AMB ointments), and 9.09 ± 0.65 log<sub>10</sub> CFU/mL (control), which differed significantly (<i>p</i> < 0.05). All of these results evidence that DMN-SD-AMB is a new approach to developing intraocular preparations for the treatment of FK.